Experimental Diabetes Research
Volume 2008 (2008), Article ID 230458, 13 pages
doi:10.1155/2008/230458
Review Article

The Effects of C-peptide on Type 1 Diabetic Polyneuropathies and Encephalopathy in the BB/Wor-rat

Anders A. F. Sima,1,2 Weixian Zhang,1 Zhen-guo Li,1 and Hideki Kamiya1,3

1Department of Pathology, Wayne State University, Detroit, MI 48201, USA
2Department of Neurology, Wayne State University, Detroit, MI 48201, USA
3Department of Medicine, Nagoya University School of Medicine, Showa-Ku, Nagoya 466-8550, Japan

Received 7 June 2007; Accepted 7 January 2008

Academic Editor: Thomas Forst

Copyright © 2008 Anders A. F. Sima et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. F. Sima, “Diabetic neuropathy: pathogenetic background, current and future therapies,” Expert Review of Neurotherapeutics, vol. 1, no. 2, pp. 225–238, 2001. View at Publisher · View at Google Scholar
  2. A. A. F. Sima and Z.-G. Li, “Diabetes, cognitive dysfunction and Alzheimer's disease,” Diabetes/Metabolism Research and Reviews. In press.
  3. Z.-G. Li, W. Zhang, and A. A. F. Sima, “Alzheimer-like changes in rat models of spontaneous diabetes,” Diabetes, vol. 56, no. 7, pp. 1817–1824, 2007. View at Publisher · View at Google Scholar · View at PubMed
  4. A. A. F. Sima, V. Nathaniel, V. Bril, T. A. J. McEwen, and D. A. Greene, “Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy,” Journal of Clinical Investigation, vol. 81, no. 2, pp. 349–364, 1988.
  5. A. A. F. Sima, “Diabetes underlies common neurological disorders,” Annals of Neurology, vol. 56, no. 4, pp. 459–461, 2004. View at Publisher · View at Google Scholar · View at PubMed
  6. A. A. F. Sima, “Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide,” Journal of the Neurological Sciences, vol. 220, no. 1-2, pp. 133–136, 2004. View at Publisher · View at Google Scholar · View at PubMed
  7. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  8. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998.
  9. A. A. F. Sima, V. Bril, V. Nathaniel, et al., “Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil,” The New England Journal of Medicine, vol. 319, no. 9, pp. 548–555, 1988.
  10. M. A. Pfeifer, M. P. Schumer, and D. A. Gelber, “Aldose reductase inhibitors: the end of an era or the need for different trial designs?,” Diabetes, vol. 46, pp. S82–S89, 1997.
  11. D. Ziegler, M. Hanefeld, K.-J. Ruhnau, et al., “Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study),” Diabetes Care, vol. 22, no. 8, pp. 1296–1301, 1999. View at Publisher · View at Google Scholar
  12. A. I. Vinik, M. T. Holland, J. M. Le Beau, F. J. Liuzzi, K. B. Stansberry, and L. B. Colen, “Diabetic neuropathies,” Diabetes Care, vol. 15, no. 12, pp. 1926–1975, 1992. View at Publisher · View at Google Scholar
  13. S. Tesfaye, L. K. Stevens, J. M. Stephenson, et al., “Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study,” Diabetologia, vol. 39, no. 11, pp. 1377–1384, 1996. View at Publisher · View at Google Scholar
  14. A. A. F. Sima, “New insights into the metabolic and molecular basis for diabetic neuropathy,” Cellular and Molecular Life Sciences, vol. 60, no. 11, pp. 2445–2464, 2003. View at Publisher · View at Google Scholar · View at PubMed
  15. A. A. F. Sima, “C-peptide and diabetic neuropathy,” Expert Opinion on Investigational Drugs, vol. 12, no. 9, pp. 1471–1488, 2003. View at Publisher · View at Google Scholar
  16. A. A. F. Sima and H. Kamiya, “Diabetic neuropathy differs in type 1 and type 2 diabetes,” in Diabetes Mellitus and Its Complications. Molecular Mechanisms, Epidemiology and Clinical Medicine, E. Adeghate, H. Saadi, A. Adem, and E. Obineche, Eds., vol. 1084 of Annals of the New York Academy of Sciences, pp. 235–249, New York Academy of Sciences, New York, NY, USA, 2006.
  17. W. Zhang, H. Kamiya, K. Ekberg, J. Wahren, and A. A. F. Sima, “C-peptide improves chronic diabetic neuropathy in type 1 diabetic BB/Wor-rats,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 1, pp. 63–70, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. A. A. F. Sima and H. Kamiya, “Insulin, C-peptide and diabetic neuropathy,” Science & Medicine, vol. 10, pp. 308–319, 2004.
  19. G. Grunberger, X. Qiang, Z.-G. Li, et al., “Molecular basis for the insulinomimetic effects of C-peptide,” Diabetologia, vol. 44, no. 10, pp. 1247–1257, 2001. View at Publisher · View at Google Scholar
  20. G. Grunberger and A. A. F. Sima, “The C-peptide signaling,” Experimental Diabesity Research, vol. 5, no. 1, pp. 25–36, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. D. F. Steiner, D. Cunningham, L. Spigelman, and B. Aten, “Insulin biosynthesis: evidence for a precursor,” Science, vol. 157, no. 3789, pp. 697–700, 1967. View at Publisher · View at Google Scholar
  22. D. F. Steiner and A. H. Rubenstein, “Proinsulin C-peptide-biological activity?,” Science, vol. 277, no. 5325, pp. 531–532, 1997. View at Publisher · View at Google Scholar
  23. A. E. Kitabchi, “Proinsulin and C peptide: a review,” Metabolism, vol. 26, no. 5, pp. 547–587, 1977.
  24. E. Fernqvist-Forbes, B.-L. Johansson, and M. J. Eriksson, “Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus,” Acta Physiologica Scandinavica, vol. 172, no. 3, pp. 159–165, 2001. View at Publisher · View at Google Scholar
  25. B.-L. Johansson, B. Linde, and J. Wahren, “Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients,” Diabetologia, vol. 35, no. 12, pp. 1151–1158, 1992. View at Publisher · View at Google Scholar
  26. B.-L. Johansson, K. Borg, E. Fernqvist-Forbes, A. Kernell, T. Odergren, and J. Wahren, “Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus,” Diabetic Medicine, vol. 17, no. 3, pp. 181–189, 2000. View at Publisher · View at Google Scholar
  27. T. Forst, T. Kunt, T. Pohlmann, et al., “Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus,” Journal of Clinical Investigation, vol. 101, no. 10, pp. 2036–2041, 1998. View at Publisher · View at Google Scholar · View at PubMed
  28. R. Rigler, A. Pramanik, P. Jonasson, et al., “Specific binding of proinsulin C-peptide to human cell membranes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 23, pp. 13318–13323, 1999. View at Publisher · View at Google Scholar
  29. Z.-G. Li, X. Qiang, A. A. F. Sima, and G. Grunberger, “C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts,” Biochemical and Biophysical Research Communications, vol. 280, no. 3, pp. 615–619, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. Y. Ido, A. Vindigni, K. Chang, et al., “Prevention of vascular and neural dysfunction in diabetic rats by C- peptide,” Science, vol. 277, no. 5325, pp. 563–566, 1997. View at Publisher · View at Google Scholar
  31. W. Zhang, M. Yorek, C. R. Pierson, Y. Murakawa, A. Breidenbach, and A. A. F. Sima, “Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat,” International Journal of Experimental Diabetes Research, vol. 2, no. 3, pp. 187–193, 2001. View at Publisher · View at Google Scholar
  32. M. J. Stevens, W. Zhang, F. Li, and A. A. F. Sima, “C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor-rats,” American Journal of Physiology, vol. 287, no. 3, pp. E497–E505, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. M. E. Jensen and E. J. Messina, “C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin,” American Journal of Physiology, vol. 276, no. 4, pp. H1223–H1228, 1999.
  34. J. Shafqat, E. Melles, K. Sigmundsson, et al., “Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects,” Cellular and Molecular Life Sciences, vol. 63, no. 15, pp. 1805–1811, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. A. A. F. Sima, “Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data,” CNS Drugs, vol. 21, supplement 1, pp. 13–23, 2007.
  36. D. A. Greene, S. A. Lattimer, and A. A. F. Sima, “Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications,” The New England Journal of Medicine, vol. 316, no. 10, pp. 599–606, 1987.
  37. M. J. Stevens, E. L. Feldman, T. P. Thomas, and D. A. Greene, “The pathogenesis of diabetic neuropathy,” in Clinical Management of Diabetic Neuropathy, A. Veves and P. M. C. Corn, Eds., pp. 13–47, Humana Press, Totowa, NJ, USA, 1997.
  38. D. Dvornik, “Hyperglycemia in the pathogenesis of diabetic complications,” in Aldose Reductase Inhibition, D. Porte, Ed., pp. 69–151, Biomedical Information, New York, NY, USA, 1987.
  39. A. A. F. Sima, W. Zhang, G. Xu, K. Sugimoto, D. Guberski, and M. A. Yorek, “A comparison of diabetic polyneuropathy in type 2 diabetic BBZDR/Wor-rats and in type 1 diabetic BB/Wor-rats,” Diabetologia, vol. 43, no. 6, pp. 786–793, 2000. View at Publisher · View at Google Scholar
  40. N. E. Cameron, M. A. Cotter, M. Basso, and T. C. Hohman, “Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats,” Diabetologia, vol. 40, no. 3, pp. 271–281, 1997. View at Publisher · View at Google Scholar
  41. J. Wahren, K. Ekberg, and H. Jörnvall, “C-peptide is a bioactive peptide,” Diabetologia, vol. 50, no. 3, pp. 503–509, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at PubMed
  43. C. R. Pierson, W. Zhang, Y. Murakawa, and A. A. F. Sima, “Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy,” Journal of Neuropathology & Experimental Neurology, vol. 62, no. 3, pp. 260–271, 2003.
  44. A. A. F. Sima and K. Sugimoto, “Experimental diabetic neuropathy: an update,” Diabetologia, vol. 42, no. 7, pp. 773–788, 1999. View at Publisher · View at Google Scholar · View at PubMed
  45. T. Brismar and A. A. F. Sima, “Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat: potential clamp analysis,” Acta Physiologica Scandinavica, vol. 113, no. 4, pp. 499–506, 1981.
  46. A. A. F. Sima and T. Brismar, “Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities,” Annals of Neurology, vol. 18, no. 1, pp. 21–29, 1985. View at Publisher · View at Google Scholar · View at PubMed
  47. A. A. F. Sima, W. Zhang, K. Sugimoto, et al., “C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor-rats,” Diabetologia, vol. 44, no. 7, pp. 889–897, 2001. View at Publisher · View at Google Scholar
  48. H. Kamiya, Y. Murakawa, W. Zhang, and A. A. F. Sima, “Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 5, pp. 448–458, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. H. Kamiya, W. Zhang, and A. A. F. Sima, “C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes,” Annals of Neurology, vol. 56, no. 6, pp. 827–835, 2004. View at Publisher · View at Google Scholar · View at PubMed
  50. H. Kamiya, W. Zhang, K. Ekberg, J. Wahren, and A. A. F. Sima, “C-peptide reverses nociceptive neuropathy in type 1 diabetes,” Diabetes, vol. 55, pp. 3581–3587, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. M. Hirade, H. Yasuda, M. Omatsu-Kanbe, R. Kikkawa, and H. Kitasato, “Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats,” Neuroscience, vol. 90, no. 3, pp. 933–939, 1999. View at Publisher · View at Google Scholar
  52. Y.-H. Lee, T.-G. Ryu, S.-J. Park, et al., “α1-adrenoceptors involvement in painful diabetic neuropathy: a role in allodynia,” NeuroReport, vol. 11, no. 7, pp. 1417–1420, 2000.
  53. K. J. Burchiel, L. C. Russell, R. P. Lee, and A. A. F. Sima, “Spontaneous activity of primary afferent neurons in diabetic BB/Wistar rats: a possible mechanism of chronic diabetic neuropathic pain,” Diabetes, vol. 34, no. 11, pp. 1210–1213, 1985. View at Publisher · View at Google Scholar
  54. W. Zhang, Y. Murakawa, K. M. Wozniak, B. Slusher, and A. A. F. Sima, “GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor-rats,” Journal of the Neurological Sciences, vol. 194, no. 1, pp. 21–28, 2002. View at Publisher · View at Google Scholar
  55. C. J. Woolf, P. Shortland, M. Reynolds, J. Ridings, T. Doubell, and R. E. Coggeshall, “Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy,” Journal of Comparative Neurology, vol. 360, no. 1, pp. 121–134, 1995. View at Publisher · View at Google Scholar · View at PubMed
  56. C. Quattrini and S. Tesfaye, “Understanding the impact of painful diabetic neuropathy,” Diabetes/Metabolism Research and Reviews, vol. 19, no. S1, pp. S2–S8, 2003. View at Publisher · View at Google Scholar · View at PubMed
  57. D. R. Tomlinson and P. Fernyhough, “Neurotrophism in diabetic neuropathy,” in Chronic Complications in Diabetes, A. A. F. Sima, Ed., pp. 167–182, Harwood Academic, Amsterdam, The Netherlands, 2000.
  58. K. Sugimoto, Y. Murakawa, and A. A. F. Sima, “Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord,” Journal of the Peripheral Nervous System, vol. 7, no. 1, pp. 44–53, 2002. View at Publisher · View at Google Scholar
  59. J. R. Singleton, A. G. Smith, and M. B. Bromberg, “Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy,” Diabetes Care, vol. 24, no. 8, pp. 1448–1453, 2001. View at Publisher · View at Google Scholar
  60. S. P. Novella, S. E. Inzucchi, and J. M. Goldstein, “The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy,” Muscle and Nerve, vol. 24, no. 9, pp. 1229–1231, 2001. View at Publisher · View at Google Scholar · View at PubMed
  61. Y. Murakawa, W. Zhang, C. R. Pierson, et al., “Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy,” Diabetes/Metabolism Research and Reviews, vol. 18, no. 6, pp. 473–483, 2002. View at Publisher · View at Google Scholar · View at PubMed
  62. A. A. F. Sima, S. A. Lattimer, S. Yagihashi, and D. A. Greene, “Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat,” Journal of Clinical Investigation, vol. 77, no. 2, pp. 474–484, 1986.
  63. C. Yu, S. Ronen, and R. Dobrowsky, “Downregulation of caveolin-1 in Schwann cells enhances ERBB2 activation and neuregulin-induced demyelination,” in Proceedings of the 17th Annual Meeting of the Diabetic Neuropathy Study Group (NEURODIAB '07), Utrecht, The Netherlands, September 2007.
  64. P. N. Hoffman, D. W. Cleveland, J. W. Griffin, P. W. Landes, N. J. Cowan, and D. L. Price, “Neurofilament gene expression: a major determinant of axonal caliber,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 10, pp. 3472–3476, 1987. View at Publisher · View at Google Scholar
  65. S. M. de Waegh, V. M.-Y. Lee, and S. T. Brady, “Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells,” Cell, vol. 68, no. 3, pp. 451–463, 1992. View at Publisher · View at Google Scholar
  66. C. R. Pierson, W. Zhang, Y. Murakawa, and A. A. F. Sima, “Early gene responses of trophic factors in nerve regeneration differ in experimental type 1 and type 2 diabetic polyneuropathies,” Journal of Neuropathology & Experimental Neurology, vol. 61, no. 10, pp. 857–871, 2002.
  67. L. Mohiuddin, P. Fernyhough, and D. R. Tomlinson, “Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes,” Diabetes, vol. 44, no. 1, pp. 25–30, 1995. View at Publisher · View at Google Scholar
  68. J. N. Scott, A. W. Clark, and D. W. Zochodne, “Neurofilament and tubulin gene expression in progressive experimental diabetes. Failure of synthesis and export by sensory neurons,” Brain, vol. 122, no. 11, pp. 2109–2118, 1999. View at Publisher · View at Google Scholar
  69. G. Xu, Y. Murakawa, C. R. Pierson, and A. A. F. Sima, “Altered tubulin and neurofilament expression and impaired axonal growth in diabetic nerve regeneration,” Journal of Neuropathology & Experimental Neurology, vol. 61, pp. 164–175, 2002.
  70. R. Medori, H. Jenich, L. Autilio-Gambetti, and P. Gambetti, “Experimental diabetic neuropathy: similar changes of slow axonal transport and axonal size in different animal models,” Journal of Neuroscience, vol. 8, no. 5, pp. 1814–1821, 1988.
  71. N. M. Sayers, L. J. Beswick, A. Middlemas, et al., “Neurotrophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozotocin-induced diabetic rats,” Diabetes, vol. 52, no. 9, pp. 2372–2380, 2003. View at Publisher · View at Google Scholar
  72. M. Terada, H. Yasuda, and R. Kikkawa, “Delayed Wallerian degeneration and increased neurofilament phosphorylation in sciatic nerves of rats with streptozotocin-induced diabetes,” Journal of the Neurological Sciences, vol. 155, no. 1, pp. 23–30, 1998. View at Publisher · View at Google Scholar
  73. P. Fernyhough, A. Gallagher, S. A. Averill, et al., “Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy,” Diabetes, vol. 48, no. 4, pp. 881–889, 1999. View at Publisher · View at Google Scholar
  74. A. Middlemas, J.-D. Delcroix, N. M. Sayers, D. R. Tomlinson, and P. Fernyhough, “Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3,” Brain, vol. 126, no. 7, pp. 1671–1682, 2003. View at Publisher · View at Google Scholar · View at PubMed
  75. M. K. Lee, Z. Xu, P. C. Wong, and D. W. Cleveland, “Neurofilaments are obligate heteropolymers in vivo,” Journal of Cell Biology, vol. 122, no. 6, pp. 1337–1350, 1993. View at Publisher · View at Google Scholar
  76. P. Grant and H. C. Pant, “Neurofilament protein synthesis and phosphorylation,” Journal of Neurocytology, vol. 29, no. 11-12, pp. 843–872, 2000. View at Publisher · View at Google Scholar
  77. A. A. F. Sima, “The development and structural characterization of the neuropathies in the spontaneously diabetic BB Wistar rat,” Metabolism, vol. 32, no. 7, supplement 1, pp. 106–111, 1983.
  78. A. A. F. Sima, M. Bouchier, and H. Christensen, “Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat: a possible early correlate of human diabetic neuropathy,” Annals of Neurology, vol. 13, no. 3, pp. 264–272, 1983. View at Publisher · View at Google Scholar · View at PubMed
  79. T. Purves, A. Middlemas, S. Agthong, et al., “A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy,” The FASEB Journal, vol. 15, no. 13, pp. 2508–2514, 2001. View at Publisher · View at Google Scholar · View at PubMed
  80. J. Brownlees, A. Yates, N. P. Bajaj, et al., “Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3,” Journal of Cell Science, vol. 113, no. 3, pp. 401–407, 2000.
  81. B. S. Li, Veeranna, J. Gu, P. Grant, and H. C. Pant, “Activation of mitogen-activated protein kinases (Erk 1 and Erk 2) cascade results in phosphorylation of NF-M tail domains in transfected NIH 3T3 cells,” European Journal of Biochemistry, vol. 262, no. 1, pp. 211–217, 1999. View at Publisher · View at Google Scholar
  82. E. Mandelkow and E.-M. Mandelkow, “Microtubules and microtubule-associated proteins,” Current Opinion in Cell Biology, vol. 7, no. 1, pp. 72–81, 1995. View at Publisher · View at Google Scholar
  83. J. Nunez and I. Fischer, “Microtubule-associated proteins (MAPs) in the peripheral nervous system during development and regeneration,” Journal of Molecular Neuroscience, vol. 8, no. 3, pp. 207–222, 1997. View at Publisher · View at Google Scholar · View at PubMed
  84. K. A. Butner and M. W. Kirschner, “Tau protein binds to microtubules through a flexible array of distributed weak sites,” Journal of Cell Biology, vol. 115, no. 3, pp. 717–730, 1991. View at Publisher · View at Google Scholar
  85. F.-Q. Zhou and W. D. Snider, “GSK-3β and microtubule assembly in axons,” Science, vol. 308, no. 5719, pp. 211–214, 2005. View at Publisher · View at Google Scholar · View at PubMed
  86. H. Kamiya, W. Zhang, and A. A. F. Sima, “Progressive axonal degeneration in type 1 BB/Wor-rats,” in Proceedings of the 17th Neurodiab Meeting (PO7 '07), Holland, The Netherlands, 2007.
  87. R. E. Schmidt, D. A. Dorsey, L. N. Beaudet, C. A. Parvin, W. Zhang, and A. A. F. Sima, “Experimental rat models of types 1 and 2 diabetes differ in sympathetic neuroaxonal dystrophy,” Journal of Neuropathology & Experimental Neurology, vol. 63, no. 5, pp. 450–460, 2004.
  88. J. W. Russell, K. A. Sullivan, A. J. Windebank, D. N. Herrmann, and E. L. Feldman, “Neurons undergo apoptosis in animal and cell culture models of diabetes,” Neurobiology of Disease, vol. 6, no. 5, pp. 347–363, 1999. View at Publisher · View at Google Scholar · View at PubMed
  89. A. M. Schmeichel, J. D. Schmelzer, and P. A. Low, “Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy,” Diabetes, vol. 52, no. 1, pp. 165–171, 2003. View at Publisher · View at Google Scholar
  90. H. Kamiya, W. Zhang, and A. A. F. Sima, “Apoptotic stress is counter balanced by survival elements preventing programmed cell death of dorsal root Ganglions in subacute type 1 diabetic BB/Wor-rats,” Diabetes, vol. 54, pp. 3288–3295, 2005.
  91. C. Cheng and D. W. Zochodne, “Sensory neurons with activated caspase-3 survive long-term experimental diabetes,” Diabetes, vol. 52, no. 9, pp. 2363–2371, 2003. View at Publisher · View at Google Scholar
  92. H. Kamiya, W. Zhang, and A. A. F. Sima, “Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BB/Wor-rats,” Diabetologia, vol. 49, no. 11, pp. 2763–2774, 2006. View at Publisher · View at Google Scholar · View at PubMed
  93. P. K. Thomas, N. G. Beamish, J. R. Small, et al., “Paranodal structure in diabetic sensory polyneuropathy,” Acta Neuropathologica, vol. 92, no. 6, pp. 614–620, 1996. View at Publisher · View at Google Scholar
  94. P. J. Dyck and C. Giannini, “Pathologic alterations in the diabetic neuropathies of humans: a review,” Journal of Neuropathology & Experimental Neurology, vol. 55, no. 12, pp. 1181–1193, 1996.
  95. A. A. F. Sima, “Diabetic polyneuropathy (Letter to the Editor),” Journal of Neuropathology & Experimental Neurology, vol. 56, no. 4, p. 458, 1997.
  96. T. Brismar, A. A. F. Sima, and D. A. Greene, “Reversible and irreversible nodal dysfunction in diabetic neuropathy,” Annals of Neurology, vol. 21, no. 5, pp. 504–507, 1987. View at Publisher · View at Google Scholar · View at PubMed
  97. P. V. Cherian, M. Kamijo, K. J. Angelides, and A. A. F. Sima, “Nodal Na+-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W-rat: prevention by aldose reductase inhibition,” Journal of Diabetes and Its Complications, vol. 10, no. 4, pp. 192–200, 1996. View at Publisher · View at Google Scholar
  98. A. A. F. Sima and P. V. Cherian, “Neuropathology of diabetic neuropathy and its correlations with neurophysiology,” Clinical Neuroscience, vol. 4, no. 6, pp. 359–364, 1997.
  99. A. A. F. Sima, W. Zhang, Z.-G. Li, Y. Murakawa, and C. R. Pierson, “Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide,” Diabetes, vol. 53, no. 6, pp. 1556–1563, 2004. View at Publisher · View at Google Scholar
  100. K. Sugimoto, Y. Murakawa, W. Zhang, G. Xu, and A. A. F. Sima, “Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms,” Diabetes/Metabolism Research and Reviews, vol. 16, no. 5, pp. 354–363, 2000. View at Publisher · View at Google Scholar
  101. Z.-G. Li, W. Zhang, and A. A. F. Sima, “C-peptide enhances insulin-mediated cell growth and protects against high glucose induced apoptosis,” Brain Path, vol. 12, supplement 41, 2003.
  102. T. Forst, D. Dufayet de la Tour, T. Kunt, et al., “Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I,” Clinical Science, vol. 98, no. 3, pp. 283–290, 2000. View at Publisher · View at Google Scholar
  103. T. Kunt, S. Schneider, A. Pfützner, et al., “The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type I diabetes mellitus,” Diabetologia, vol. 42, no. 4, pp. 465–471, 1999. View at Publisher · View at Google Scholar
  104. Y. Ohtomo, A. Aperia, B. Sahlgren, B.-L. Johansson, and J. Wahren, “C-peptide stimulates rat renal tubular Na+, K+-ATPase activity in synergism with neuropeptide Y,” Diabetologia, vol. 39, no. 2, pp. 199–205, 1996. View at Publisher · View at Google Scholar
  105. Z. Zhong, A. Davidescu, I. Ehrén, et al., “C-peptide stimulates ERK 1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells,” Diabetologia, vol. 48, no. 1, pp. 187–197, 2005. View at Publisher · View at Google Scholar · View at PubMed
  106. R. Pop-Busi, A. A. F. Sima, and M. Stevens, “Diabetic neuropathy and oxidative stress,” Diabetes/Metabolism Research and Reviews, vol. 22, no. 4, pp. 257–273, 2006. View at Publisher · View at Google Scholar · View at PubMed
  107. N. E. Cameron, M. A. Cotter, V. Archibald, K. C. Dines, and E. K. Maxfield, “Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats,” Diabetologia, vol. 37, no. 5, pp. 449–459, 1994. View at Publisher · View at Google Scholar
  108. N. E. Cameron and M. A. Cotter, “Oxidative stress and abnormal lipid metabolism in diabetic complication,” in Chronic Complications in Diabetes: Animal Models and Chronic Complications, A. A. F. Sima, Ed., pp. 97–130, Harwood Academic, Amsterdam, The Netherlands, 1997.
  109. J. R. Requena and J. W. Baynes, “Studies in animal models on the role of glycation and advanced glycation end products (AGE's) in the pathogenes of diabetic complications: pitfalls and limitations,” in Chronic Complications in Diabetes: Animal Models and Chronic Complications, A. A. F. Sima, Ed., pp. 43–70, Harwood Academic, Amsterdam, The Netherlands, 1999.
  110. T. Wallerath, T. Kunt, T. Forst, et al., “Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide,” Nitric Oxide, vol. 9, no. 2, pp. 95–102, 2003. View at Publisher · View at Google Scholar
  111. T. Kitamura, K. Kimura, K. Makondo, et al., “Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats,” Diabetologia, vol. 46, no. 12, pp. 1698–1705, 2003. View at Publisher · View at Google Scholar · View at PubMed
  112. R. Scalia, K. Coyle, B. Levine, G. Booth, and A. Lefer, “C-peptide inhibits leucocyte-endothelium interaction in the microcirculation during endothelial dysfunction,” The FASEB Journal, vol. 14, no. 14, pp. 2357–2364, 2000. View at Publisher · View at Google Scholar · View at PubMed
  113. H. Li, L. Xu, J. C. Dunbar, C. B. Dhabuwala, and A. A. F. Sima, “Effects of C-peptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells*1,” Urology, vol. 64, no. 3, pp. 622–627, 2004. View at Publisher · View at Google Scholar · View at PubMed
  114. M. A. Cotter, K. Ekberg, J. Wahren, and N. E. Cameron, “Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition,” Diabetes, vol. 52, no. 7, pp. 1812–1817, 2003. View at Publisher · View at Google Scholar
  115. Z.-G. Li, W. Zhang, and A. A. F. Sima, “C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 5, pp. 375–385, 2003. View at Publisher · View at Google Scholar · View at PubMed
  116. Z.-G. Li, W. Zhang, and A. A. F. Sima, “The role of impaired insulin/IGF action in primary diabetic encephalopathy,” Brain Research, vol. 1037, no. 1-2, pp. 12–24, 2005. View at Publisher · View at Google Scholar · View at PubMed
  117. Z.-G. Li, W. Zhang, and A. A. F. Sima, “C-peptide prevents hippocampal apoptosis in type 1 diabetes,” International Journal of Experimental Diabetes Research, vol. 3, no. 4, pp. 241–245, 2002. View at Publisher · View at Google Scholar
  118. C. R. Pierson, W. Zhang, and A. A. F. Sima, “Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration,” Journal of Neuropathology & Experimental Neurology, vol. 62, no. 7, pp. 765–779, 2003.
  119. H. Kamiya, W. Zhang, and A. A. F. Sima, “Apoptotic stress is counterbalanced by survival elements preventing programmed cell death of dorsal root ganglions in subacute type 1 diabetic BB/Wor-rats,” Diabetes, vol. 54, no. 11, pp. 3288–3295, 2005. View at Publisher · View at Google Scholar
  120. K. Yamamoto, A. C. Merry, and A. A. F. Sima, “An orderly development of paranodal axoglial junctions and bracelets of Nageotte in the rat sural nerve,” Developmental Brain Research, vol. 96, no. 1-2, pp. 36–45, 1996. View at Publisher · View at Google Scholar
  121. L. Kramer, P. Fasching, C. Madl, et al., “Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment,” Diabetes, vol. 47, no. 12, pp. 1909–1914, 1998. View at Publisher · View at Google Scholar
  122. A. Ott, R. P. Stolk, F. van Harskamp, H. A. P. Pols, A. Hofman, and M. M. B. Breteler, “Diabetes mellitus and the risk of dementia: the Rotterdam study,” Neurology, vol. 53, no. 9, pp. 1937–1942, 1999.
  123. Z. Arvanitakis, R. S. Wilson, J. L. Bievas, D. A. Evans, and D. A. Bennett, “Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function,” Archives of Neurology, vol. 61, no. 5, pp. 661–666, 2004. View at Publisher · View at Google Scholar · View at PubMed
  124. E. J. Schoenle, D. Schoenle, L. Mokiosari, and R. H. Largo, “Impaired intellectual development in children with type I diabetes: association with HbA1c, age at diagnosis and sex,” Diabetologia, vol. 45, no. 1, pp. 108–114, 2002. View at Publisher · View at Google Scholar
  125. C. M. Ryan, “Neurobehavioral complications of type 1 diabetes. Examination of possible risk factors,” Diabetes Care, vol. 11, no. 1, pp. 86–93, 1988. View at Publisher · View at Google Scholar
  126. A. A. F. Sima, H. Kamiya, and Z.-G. Li, “Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 187–197, 2004. View at Publisher · View at Google Scholar · View at PubMed
  127. A. Kurita, S. Mochio, and Y. Isogai, “Changes in auditory P300 event-related potentials and brainstem evoked potentials in diabetes mellitus,” Acta Neurologica Scandinavica, vol. 92, no. 4, pp. 319–323, 1995.
  128. C. S. Holmes and L. C. Richman, “Cognitive profiles of children with insulin-dependent diabetes,” Journal of Developmental and Behavioral Pediatrics, vol. 6, no. 6, pp. 323–326, 1985.
  129. M. Lunetta, A. R. Damanti, G. Fabbri, M. Lombardo, M. Di Mauro, and L. Mughini, “Evidence by magnetic resonance imaging of cerebral alterations of atrophy type in young insulin-dependent diabetic patients,” Journal of Endocrinological Investigation, vol. 17, no. 4, pp. 241–245, 1994.
  130. P. Perros, I. J. Deary, R. J. Sellar, J. J. K. Best, and B. M. Frier, “Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia,” Diabetes Care, vol. 20, no. 6, pp. 1013–1018, 1997. View at Publisher · View at Google Scholar
  131. J. Dey, A. Misra, N. G. Desai, A. K. Mahapatra, and M. V. Padma, “Cognitive function in younger type II diabetes,” Diabetes Care, vol. 20, no. 1, pp. 32–35, 1997. View at Publisher · View at Google Scholar
  132. C. M. Ryan, “Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis,” Pediatric Diabetes, vol. 7, no. 5, pp. 289–297, 2006. View at Publisher · View at Google Scholar · View at PubMed
  133. A. Kamal, G.-J. Biessels, I. J. A. Urban, and W. H. Gispen, “Hippocampal synaptic plasticity in streptozotocin-diabetic rats: impairment of long-term potentiation and facilitation of long-term depression,” Neuroscience, vol. 90, no. 3, pp. 737–745, 1999. View at Publisher · View at Google Scholar
  134. G.-J. Biessels, A. Kamal, I. J. A. Urban, B. M. Spruijt, D. W. Erkelens, and W. H. Gispen, “Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment,” Brain Research, vol. 800, no. 1, pp. 125–135, 1998. View at Publisher · View at Google Scholar
  135. Z.-G. Li, W. Zhang, G. Grunberger, and A. A. F. Sima, “Hippocampal neuronal apoptosis in type 1 diabetes,” Brain Research, vol. 946, no. 2, pp. 221–231, 2002. View at Publisher · View at Google Scholar
  136. A. A. F. Sima and Z.-G. Li, “The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats,” Diabetes, vol. 54, no. 5, pp. 1497–1505, 2005. View at Publisher · View at Google Scholar